NICE Guidance: Epcoritamab for Follicular Lymphoma

NICE Technology Appraisals

Published March 11th, 2026

Detected March 12th, 2026

Summary

NICE has published technology appraisal guidance (TA1139) recommending epcoritamab (Tepkinly) for treating relapsed or refractory follicular lymphoma in adults after two or more lines of systemic treatment. The guidance outlines evidence-based recommendations for healthcare professionals.

View original document View source feed page

What changed

NICE has issued final guidance (TA1139) recommending the use of epcoritamab (Tepkinly) for adults with relapsed or refractory follicular lymphoma who have undergone at least two prior lines of systemic treatment. This guidance provides evidence-based recommendations for healthcare professionals in the UK.

Healthcare professionals are expected to consider this guidance when making treatment decisions, in consultation with patients. Commissioners and providers must ensure funding is available for its application. Any adverse events related to the treatment should be reported to the MHRA via the Yellow Card Scheme. The guidance also touches upon commercial arrangements and environmental sustainability considerations.

What to do next

Review NICE guidance TA1139 regarding epcoritamab for follicular lymphoma.
Consult with patients on treatment options in line with the guidance.
Ensure reporting of adverse events via the Yellow Card Scheme.

Source document (simplified)

Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment

Technology appraisal guidance
TA1139
Published:

11 March 2026

Download guidance (PDF)

Overview

Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment in adults.

Last reviewed: 11 March 2026

Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.

Commercial arrangement

There is a simple discount patient access scheme for epcoritamab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact pricing@abbvie.com for details.

Guidance development process

How we develop NICE technology appraisal guidance

Your responsibility

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.

Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.